March 1, 2017

CABM was chartered in 1985 by the New Jersey Commission on Science and Technology as a center of excellence to enhance research and training programs in the life sciences at UMDNJ and Rutgers University. With the vision and expert leadership of Founding Director Aaron J. Shatkin, CABM developed into an internationally recognized teaching and research institute. Over the past 30 years, CABM laboratories have attracted more than $300 million in research funding and have provided training experiences for more than a thousand graduate students and postdoctoral fellows as well as numerous undergraduate students.

CABM scientists are dedicated to their mission to make fundamental discoveries in biomedical research, develop new technologies, and translate these to improve human health. Research programs at CABM are increasing our understanding of the molecular basis of infectious disease, cancer, and neurodevelopmental and neurodegenerative disorders leading to new therapies for diseases such as AIDS, influenza, bacterial infections, leukemia/lymphoma, autism, and metabolic disorders.

CABM looks forward to new opportunities that have been afforded by the integration of UMDNJ into Rutgers University. As a jointly administered center since its inception, CABM has benefited greatly from the combined strengths of the two universities. CABM continues to serve as a hub for basic science activities, bridging departments at Rutgers School of Arts and Sciences and RBHS-Robert Wood Johnson Medical School. This year we are excited to be embarking on a search for a new director. As we embrace change that will enhance our future, we remain committed to perpetuating the CABM culture of excellence, a spirit of collaboration, and an environment that facilitates the joy of discovery.

Ann Stock, Ph.D.

Interim Director
Center for Advanced Biotechnology and Medicine